key: cord-0965534-7295w0ic authors: Sarma, Aartik; Christenson, Stephanie; Mick, Eran; Deiss, Thomas; DeVoe, Catherine; Pisco, Angela; Ghale, Rajani; Jauregui, Alejandra; Byrne, Ashley; Moazed, Farzad; Spottiswoode, Natasha; Sinha, Pratik; Zha, Beth; Neff, Norma; Tan, Michelle; Serpa, Paula Hayakawa; Ansel, K. Mark; Wilson, Jennifer; Leligdowicz, Aleksandra; Seigel, Emily; Sirota, Marina; DeRisi, Joseph; Matthay, Michael; Consortium, COMET; Hendrickson, Carolyn; Kangelaris, Kirsten; Krummel, Matthew; Woodruff, Prescott; Erle, David; Calfee, Carolyn; Langelier, Charles title: COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone date: 2021-01-14 journal: Res Sq DOI: 10.21203/rs.3.rs-141578/v1 sha: 0bb794bc328e4fecaa28a800a6e71920a87b12cd doc_id: 965534 cord_uid: 7295w0ic We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with the acute respiratory distress syndrome (ARDS) from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 was characterized by impaired interferon-stimulated gene expression (ISG). We found that the relationship between SARS-CoV-2 viral load and expression of ISGs was decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone. In its most severe form, coronavirus disease 2019 (COVID-19) can precipitate the acute 61 respiratory distress syndrome (ARDS), which is characterized by low arterial oxygen 62 concentrations, alveolar injury and a dysregulated inflammatory response in the lungs 1 We conducted a prospective case-control study of 52 adults requiring mechanical 82 ventilation ( Table 1) We compared TA gene expression between COVID-ARDS and Other-ARDS patients 91 (Methods, Fig. 1a, Supplementary Data 2) and identified 696 differentially expressed genes at 92 an adjusted P-value < 0.1, as well as differentially activated pathways using Ingenuity Pathway 93 Analysis (IPA) 9 . Notably, we did not observe elevated expression of genes encoding canonical 94 proinflammatory cytokines, such as IL-1 or IL-6, in COVID-ARDS compared to Other-ARDS. In 95 fact, IL-1, IL-6 and several other cytokine signaling pathways were more highly activated in Other-ARDS, whereas COVID-ARDS patients had comparable inflammatory pathway activation 97 to No-ARDS controls (Fig. 1b, Supplementary Data 3) . We also found attenuation of the 98 proinflammatory HIF-1a and nitric oxide signaling pathways in COVID-ARDS compared to Other-99 ARDS patients. To relate these lower respiratory tract findings to systemic inflammatory 100 responses, we also assessed circulating plasma cytokines. We found no difference in IL-6 or IL- Evaluation of genes with the most significant expression differences in COVID-ARDS 104 compared to Other-ARDS did, however, reveal several differences in genes regulating immunity At the pathway level, we observed activation of PTEN signaling in COVID-ARDS 111 compared to both Other-ARDS and No-ARDS patients (Fig. 1b, Supplementary Data 3) . PTEN severe COVID-19 6 . Granulocyte colony stimulating factor (G-CSF) was also significant, which is 131 intriguing given that a recent clinical trial found a mortality benefit in COVID-19 patients treated 132 with this agent 15 . Other corticosteroids (fluticasone, prednisolone) as well as omega-3 fatty acids 133 (eicosapentenoic and docosahexaenoic acids) were also predicted to counteract the 134 transcriptional profile of COVID-ARDS with respect to comparator groups and thus may 135 represent possible therapeutic agents (Fig. 1c, Supplementary Data 6) . As our analysis did not reveal evidence of a cytokine storm in COVID-19 ARDS, we 137 hypothesized that other steroid-responsive pathways may be responsible for the therapeutic 138 benefit of dexamethasone. Although commonly thought of as indiscriminate immunosuppressive 139 medications, glucocorticoids affect diverse biological processes. We therefore proceeded to examine the genes comprising the transcriptional signature of COVID-ARDS that were also 141 predicted to be regulated by dexamethasone (Supplementary Data 7) . Interestingly, both 142 dexamethasone and G-CSF were predicted to attenuate the expression of several genes highly 143 upregulated in COVID-ARDS versus controls (e.g., P2YR14) as well as other genes with well- Empirical Bayesian adaptive shrinkage estimators for log2-fold change were fit using ashr 32 . We 244 generated heatmaps of the top 50 differentially expressed genes by absolute log2-fold change. For visualization, gene expression was normalized using the variance stabilizing transformation, 246 centered, and z-scaled. Heatmaps were generated using the pheatmap package. Patients were 247 clustered using Euclidean distance and genes were clustered using Manhattan distance. FBN2 MZB1 GABRB3 DEFB115 LGI1 FRK OR4F17 TBC1D8B ADAMTSL3 NMNAT3 PIGL AMDHD1 LRRTM4 AC005726.1 SLC15A1 PTRH1 SLC12A5 SSBP2 WDR72 NEDD4 ATP1A3 DUOXA2 DUOX2 GSDMB MPRIP MX1 HERC6 USP18 CSF3 PML ISG15 PRKD2 RUBCN HELZ2 Other-viral Non-viral logFC -5 0 5 Interferon-λ1 Interferon-α1 Interferon-β1 Whiskers extend from the hinge to the largest (smallest, respectively) value no more than 522 1.5*IQR away from the hinge, where IQR is the interquartile range. The y-axis in each panel 523 was trimmed at the maximum value among the three patient groups of 1.5*IQR above the third 524 quartile. Pairwise comparisons between patient groups were performed with a two-sided Mann- Acute respiratory distress syndrome COVID-19: consider cytokine storm syndromes and immunosuppression Imbalanced host response to SARS-CoV-2 drives development of 375 COVID-19 Complex Immune Dysregulation in COVID-19 Patients 377 with Severe Respiratory Failure Cytokine profile in plasma of severe COVID-19 does not differ from 379 ARDS and sepsis Dexamethasone in Hospitalized Patients with Covid-381 19 -Preliminary Report Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients COVID-19 severity correlates with airway epithelium-immune cell 386 interactions identified by single-cell analysis Causal analysis approaches in 388 Ingenuity Pathway Analysis UDP-glucose promotes neutrophil recruitment in the lung STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation 392 resolution in stroke mice The functions of tumor suppressor PTEN in innate and adaptive 394 immunity Myeloid PTEN Promotes Inflammation but Impairs Bactericidal 396 Activities during Murine Pneumococcal Pneumonia SARS-CoV-2 entry factors are highly expressed in 399 nasal epithelial cells together with innate immune genes Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for 402 Regulation of inflammatory gene expression in 405 macrophages by epithelial-stromal interaction 1 (Epsti1) STAT signaling in inflammation Upper airway gene expression reveals suppressed immune responses to 409 SARS-CoV-2 compared with other respiratory viruses Impaired type I interferon activity and inflammatory responses in severe 411 COVID-19 patients Multi-cohort analysis of host immune response identifies conserved 413 protective and detrimental modules associated with severity irrespective of virus Sepsis therapies: learning from 30 years of failure of 417 translational research to propose new leads Assessment of Clinical Criteria for Sepsis: For the Third International 419 Sepsis-3) Integrating host response and unbiased microbe detection for lower 421 respiratory tract infection diagnosis in critically ill adults Acute respiratory distress syndrome: the Berlin definition United States Centers for Disease Control and Prevention. CDC/NHSN Surveillance 426 Definitions for Specific Types of Infections Evaluation of the External RNA Controls Consortium (ERCC) reference 428 material using a modified Latin square design Near-optimal probabilistic RNA-seq 430 quantification Differential analyses for RNA-seq: transcript-432 level estimates improve gene-level inferences Moderated estimation of fold change and dispersion for 434 RNA-seq data with DESeq2 Data-driven hypothesis weighting 436 increases detection power in genome-scale multiple testing Controlling the False Discovery Rate: A Practical and 439 Powerful Approach to Multiple Testing False discovery rates: a new deal Ingenuity Systems. Ingenuity Upstream Regulator Analysis in IPA Robust enumeration of cell subsets from tissue expression profiles. 446 A molecular cell atlas of the human lung from single-cell RNA 448 sequencing Gene set enrichment analysis: A knowledge-based approach for 450 interpreting genome-wide expression profiles A molecular cell atlas of the human lung from single cell RNA 453 sequencing